U.S. markets closed
  • S&P Futures

    4,144.50
    -9.00 (-0.22%)
     
  • Dow Futures

    33,086.00
    -69.00 (-0.21%)
     
  • Nasdaq Futures

    14,025.50
    -9.50 (-0.07%)
     
  • Russell 2000 Futures

    2,226.30
    -4.30 (-0.19%)
     
  • Crude Oil

    71.70
    +0.06 (+0.08%)
     
  • Gold

    1,769.40
    +0.40 (+0.02%)
     
  • Silver

    25.94
    -0.02 (-0.09%)
     
  • EUR/USD

    1.1871
    -0.0040 (-0.33%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    20.70
    +2.95 (+16.62%)
     
  • GBP/USD

    1.3812
    -0.0112 (-0.80%)
     
  • USD/JPY

    110.1790
    -0.0520 (-0.05%)
     
  • BTC-USD

    35,718.67
    +19.80 (+0.06%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.22 (-0.19%)
     

AscellaHealth Launches Industry Newsletter, "Directions in Specialty Pharmacy": Features Quality & Cost Containment Strategies for Medical and Pharmacy Benefit

·2 min read

AscellaHealth, a national specialty pharmacy benefit manager (SPBMTM) serving commercial, Medicare and Medicaid segments, is pleased to announce the launch of its quarterly newsletter, "Directions in Specialty Pharmacy." Featuring the latest information and support for specialty pharmacy benefit management, this go-to resource shines a light on significant industry trends and advances and addresses an array of concerns for the expansive communities focused on specialty pharmaceuticals, including employers, plan sponsors, payers, manufacturers, providers, advocacy groups, government regulators and industry consultants.

Click here to read the inaugural issue.

"We’re very excited to bring these insights and perspectives to industry stakeholders at such a critical time in our health system’s evolution," says Dea Belazi, president and CEO, AscellaHealth. "This newsletter exemplifies our dedication to improving specialty pharmacy benefit management to help propel the industry forward. We anticipate that this publication will further strengthen our robust relationships within the employer and payer communities, as well as the pharma and biotech industries."

The first issue features:

  • How self-insured companies can embrace patient-first specialty benefit management to optimize the value of specialty drugs and reduce costs

  • How alternative payment models can help employers and plan sponsors curb the staggering costs of expensive new gene therapies for rare diseases

  • Personal insight from Michelle Rice, chief external affairs officer, National Hemophilia Foundation (NHF), who has played a pivotal role in enhancing access to care for people with hemophilia

  • Critical insights from key industry thought leaders, including specialty pharma trends that impact employer benefits purchasing decisions; minimizing costs for rare and orphan drugs; and how the specialty pharmaceutical industry will adapt to the new normal after the COVID-19 pandemic

Belazi adds, "AscellaHealth will continue to serve at the forefront of the burgeoning specialty marketplace, proactively providing education and information, and helping employers and other stakeholders create accountability and predictability around specialty drugs."

About AscellaHealth

AscellaHealth, a national specialty pharmacy benefit manager (SPBMTM), serving commercial, Medicare and Medicaid segments, offers high quality prescription drug benefit management services. Complemented by other customizable services, such as carved-out specialty pharmacy services and cost-savings programs, AscellaHealth provides a unique, proprietary service portfolio. Visit www.ascellahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005955/en/

Contacts

Media:
Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54